Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$51.32−0.33 (-0.64%)
Close on Nov 18, 2026Market cap $7.13BP/E –Yield –
Cytokinetics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cytokinetics's revenue for the twelve months ending Jun 30, 2026 was $67.67M, down 21.1% year over year. For fiscal 2025 it was $88.04M, up 376.6% from the year before. Over ten years it grew 11.9% a year on average. The highest annual figure on record is $106.41M in fiscal 2016.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.04M | +376.6% |
| FY2024 | Dec 31, 2024 | $18.47M | +145.3% |
| FY2023 | Dec 31, 2023 | $7.53M | -92.0% |
| FY2022 | Dec 31, 2022 | $94.59M | +34.3% |
| FY2021 | Dec 31, 2021 | $70.43M | +26.2% |
| FY2020 | Dec 31, 2020 | $55.83M | +107.8% |
| FY2019 | Dec 31, 2019 | $26.87M | -14.7% |
| FY2018 | Dec 31, 2018 | $31.50M | +135.6% |
| FY2017 | Dec 31, 2017 | $13.37M | -87.4% |
| FY2016 | Dec 31, 2016 | $106.41M | +271.3% |
| FY2015 | Dec 31, 2015 | $28.66M | -38.9% |
| FY2014 | Dec 31, 2014 | $46.94M | +53.2% |
| FY2013 | Dec 31, 2013 | $30.65M | +305.5% |
| FY2012 | Dec 31, 2012 | $7.56M | +89.0% |
| FY2011 | Dec 31, 2011 | $4.00M | +55.2% |
| FY2010 | Dec 31, 2010 | $2.58M | -96.8% |
| FY2009 | Dec 31, 2009 | $81.54M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $28.62M | -57.1% |
| Q1 FY2026 | Mar 31, 2026 | $19.36M | +1125.8% |
| Q4 FY2025 | Dec 31, 2025 | $17.76M | +4.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.94M | +318.1% |
| Q2 FY2025 | Jun 30, 2025 | $66.77M | +26714.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.58M | +89.1% |
| Q4 FY2024 | Dec 31, 2024 | $16.93M | +912.4% |
| Q3 FY2024 | Sep 30, 2024 | $463.00K | +22.5% |
| Q2 FY2024 | Jun 30, 2024 | $249.00K | -71.3% |
| Q1 FY2024 | Mar 31, 2024 | $835.00K | -81.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.67M | -14.6% |
| Q3 FY2023 | Sep 30, 2023 | $378.00K | -85.0% |
| Q2 FY2023 | Jun 30, 2023 | $867.00K | -99.0% |
| Q1 FY2023 | Mar 31, 2023 | $4.61M | +301.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.96M | -96.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.52M | -53.7% |
| Q2 FY2022 | Jun 30, 2022 | $88.97M | +3029.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.15M | -82.5% |
| Q4 FY2021 | Dec 31, 2021 | $55.60M | +727.1% |
| Q3 FY2021 | Sep 30, 2021 | $5.44M | -87.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.84M | -20.9% |
| Q1 FY2021 | Mar 31, 2021 | $6.55M | +71.2% |
| Q4 FY2020 | Dec 31, 2020 | $6.72M | +29.0% |
| Q3 FY2020 | Sep 30, 2020 | $41.69M | +588.5% |
| Q2 FY2020 | Jun 30, 2020 | $3.59M | -49.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.83M | -54.8% |
| Q4 FY2019 | Dec 31, 2019 | $5.21M | -44.4% |
| Q3 FY2019 | Sep 30, 2019 | $6.06M | -43.1% |
| Q2 FY2019 | Jun 30, 2019 | $7.14M | +14.8% |
| Q1 FY2019 | Mar 31, 2019 | $8.46M | +60.7% |
| Q4 FY2018 | Dec 31, 2018 | $9.38M | – |
| Q3 FY2018 | Sep 30, 2018 | $10.64M | +72.2% |
| Q2 FY2018 | Jun 30, 2018 | $6.22M | +103.6% |
| Q1 FY2018 | Mar 31, 2018 | $5.27M | +26.8% |
| Q4 FY2017 | Dec 31, 2017 | -$18.00K | -100.1% |
| Q3 FY2017 | Sep 30, 2017 | $6.18M | -89.5% |
| Q2 FY2017 | Jun 30, 2017 | $3.05M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.15M | – |
| Q4 FY2016 | Dec 31, 2016 | $33.14M | – |
| Q3 FY2016 | Sep 30, 2016 | $59.05M | – |
See a number that looks wrong?